2014
KRAS mutation testing in clinical practice
Perincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Review Of Molecular Diagnostics 2014, 15: 375-384. PMID: 25487540, DOI: 10.1586/14737159.2015.986102.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKRAS mutation testingKRAS mutationsMetastatic colorectal carcinomaLung cancer patientsMutations of KRASCommon human malignanciesMutation testingCombinatorial therapeutic strategiesCancer patientsColorectal carcinomaThyroid cancerClinical aggressivenessClinical OncologyTherapeutic strategiesClinical practiceMolecular testingCytological specimensHuman malignanciesPrecision medicinePatientsCancerEssential biomarkersDownstream effectorsCurrent practiceMutations
2009
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal Of Cancer 2009, 102: 134-143. PMID: 19920829, PMCID: PMC2813756, DOI: 10.1038/sj.bjc.6605448.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, PapillaryAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityCell Line, TumorComplement System ProteinsCytotoxicity, ImmunologicDimerizationDrug Screening Assays, AntitumorDrug SynergismFemaleHumansImmunoglobulin GIn Vitro TechniquesInterleukin-2Killer Cells, NaturalLymphocytesMiddle AgedReceptor, ErbB-2Signal TransductionTrastuzumabUterine NeoplasmsConceptsAntibody-dependent cell-mediated cytotoxicityUSPC cell linesHER2/neu expressionComplement-dependent cytotoxicityStrong antibody-dependent cell-mediated cytotoxicitySerous papillary adenocarcinomaNeu expressionHER2/neuPapillary adenocarcinomaHigh HER2/neu expressionLow HER2/neu expressionCell linesH chromium release assaysPrimary USPC cell linesAdvanced/recurrentCombination of pertuzumabCell-mediated cytotoxicityHumanised monoclonal antibodyChromium release assaysC-erbB2 gene amplificationActivity of pertuzumabNew therapeutic agentsProliferation-based assaysType II receptorEndometrial cancer
2004
STAT3-Mediated Signaling in the Determination of Rod Photoreceptor Cell Fate in Mouse Retina
Zhang SS, Wei J, Qin H, Zhang L, Xie B, Hui P, Deisseroth A, Barnstable CJ, Fu XY. STAT3-Mediated Signaling in the Determination of Rod Photoreceptor Cell Fate in Mouse Retina. Investigative Ophthalmology & Visual Science 2004, 45: 2407-2412. PMID: 15223824, DOI: 10.1167/iovs.04-0003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCalcium-Calmodulin-Dependent Protein KinasesCell DifferentiationCell DivisionCiliary Neurotrophic FactorDNA-Binding ProteinsEnzyme InhibitorsFemaleFlavonoidsFluorescent Antibody Technique, IndirectImmunoenzyme TechniquesInterleukin-6Leukemia Inhibitory FactorMAP Kinase Signaling SystemMiceMitogen-Activated Protein KinasesPregnancyRetinaRetinal Rod Photoreceptor CellsSignal TransductionSTAT3 Transcription FactorTrans-ActivatorsConceptsMitogen-activated protein kinaseCiliary neurotrophic factorLeukemia inhibitory factorPhotoreceptor cell fateCell fate decisionsRod photoreceptor cell fateRod photoreceptor differentiationDominant negative STAT3Mouse retina developmentActivator of transcriptionMAPK inhibitor PD98059Activation of STAT3Fate decisionsCell fateTransduction pathwaysProtein kinasePhotoreceptor developmentRod developmentSignal transducerInhibitor PD98059Photoreceptor differentiationRetina explant culturesMouse retinaMAPK pathwayRetina development